GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » EV-to-EBIT

GeneTether Therapeutics (XCNQ:GTTX) EV-to-EBIT : 0.52 (As of Oct. 31, 2024)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GeneTether Therapeutics's Enterprise Value is C$-0.46 Mil. GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was C$-0.89 Mil. Therefore, GeneTether Therapeutics's EV-to-EBIT for today is 0.52.

The historical rank and industry rank for GeneTether Therapeutics's EV-to-EBIT or its related term are showing as below:

XCNQ:GTTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.6   Med: 0   Max: 1.08
Current: 0.53

During the past 4 years, the highest EV-to-EBIT of GeneTether Therapeutics was 1.08. The lowest was -31.60. And the median was 0.00.

XCNQ:GTTX's EV-to-EBIT is ranked better than
76.61% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs XCNQ:GTTX: 0.53

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. GeneTether Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was C$0.52 Mil. GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was C$-0.89 Mil. GeneTether Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -169.39%.


GeneTether Therapeutics EV-to-EBIT Historical Data

The historical data trend for GeneTether Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics EV-to-EBIT Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -1.03 0.28

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.12 0.28 0.57 -0.59

Competitive Comparison of GeneTether Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, GeneTether Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneTether Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's EV-to-EBIT falls into.



GeneTether Therapeutics EV-to-EBIT Calculation

GeneTether Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.464/-0.888
=0.52

GeneTether Therapeutics's current Enterprise Value is C$-0.46 Mil.
GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics  (XCNQ:GTTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GeneTether Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-0.888/0.524235
=-169.39 %

GeneTether Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was C$0.52 Mil.
GeneTether Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneTether Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin. Their platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.

GeneTether Therapeutics Headlines

No Headlines